US eyes more challenges to "reverse payment" settlements
This article was originally published in Scrip
Executive Summary
Innovators and generics companies that enter into "reverse payment" patent settlements could still face a US regulatory challenge despite theFederal Trade Commission's ongoing legal action againstCephalon.